SI3723858T1 - Bispecifično protitelo FIXAXFX s skupno lahko verigo - Google Patents
Bispecifično protitelo FIXAXFX s skupno lahko verigoInfo
- Publication number
- SI3723858T1 SI3723858T1 SI201930150T SI201930150T SI3723858T1 SI 3723858 T1 SI3723858 T1 SI 3723858T1 SI 201930150 T SI201930150 T SI 201930150T SI 201930150 T SI201930150 T SI 201930150T SI 3723858 T1 SI3723858 T1 SI 3723858T1
- Authority
- SI
- Slovenia
- Prior art keywords
- fixaxfx
- light chain
- bispecific antibody
- common light
- common
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820977.5A GB201820977D0 (en) | 2018-12-21 | 2018-12-21 | Fixaxfx bispecific antibody with commomn light chain |
| GBGB1906816.2A GB201906816D0 (en) | 2019-05-15 | 2019-05-15 | FIXaxFX bispecific antibody with common light chain |
| GBGB1908190.0A GB201908190D0 (en) | 2019-06-07 | 2019-06-07 | Fixaxfx bispecific antibody with common light chain |
| EP19836806.0A EP3723858B1 (en) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecific antibody with common light chain |
| PCT/EP2019/086808 WO2020128049A1 (en) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecific antibody with common light chain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3723858T1 true SI3723858T1 (sl) | 2022-04-29 |
Family
ID=69167786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930150T SI3723858T1 (sl) | 2018-12-21 | 2019-12-20 | Bispecifično protitelo FIXAXFX s skupno lahko verigo |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10815308B2 (https=) |
| EP (2) | EP4015538A1 (https=) |
| JP (1) | JP7530362B2 (https=) |
| KR (1) | KR20210118085A (https=) |
| CN (1) | CN113453757B (https=) |
| BR (1) | BR112021012065A2 (https=) |
| CA (1) | CA3123177A1 (https=) |
| DK (1) | DK3723858T3 (https=) |
| ES (1) | ES2901683T3 (https=) |
| HR (1) | HRP20220088T1 (https=) |
| HU (1) | HUE057634T2 (https=) |
| LT (1) | LT3723858T (https=) |
| PL (1) | PL3723858T3 (https=) |
| PT (1) | PT3723858T (https=) |
| RS (1) | RS62848B1 (https=) |
| SI (1) | SI3723858T1 (https=) |
| TW (1) | TWI772724B (https=) |
| WO (1) | WO2020128049A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| US10815308B2 (en) | 2018-12-21 | 2020-10-27 | Kymab Limited | FIXaxFX bispecific antibody with common light chain |
| CN113939541A (zh) * | 2019-05-15 | 2022-01-14 | 科马布有限公司 | 改进的λ抗体 |
| GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
| CN115728433B (zh) * | 2021-08-27 | 2024-11-15 | 联邦生物科技(珠海横琴)有限公司 | IgG4型单克隆抗体电荷异质性的离子交换色谱检测方法 |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| EP4473008A4 (en) * | 2022-01-31 | 2025-12-31 | Childrens Hospital Philadelphia | COMPOSITIONS AND METHODS OF TREATMENT OF A FACTOR IX DEFICIENCY |
| US12098400B2 (en) | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
| GB202319967D0 (en) | 2023-12-22 | 2024-02-07 | Epsilogen Ltd | Heteromultimeric proteins |
| WO2026036047A1 (en) * | 2024-08-08 | 2026-02-12 | Altus Enterprises, Inc. | Antibody molecules to fixa and fx and uses thereof |
| WO2026037918A1 (en) | 2024-08-14 | 2026-02-19 | Epsilogen Ltd | Heteromultimeric proteins |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| AU2003271186A1 (en) | 2003-10-14 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| PT1876236E (pt) | 2005-04-08 | 2014-10-22 | Chugai Pharmaceutical Co Ltd | Anticorpos para substituição da função do factor de coagulação sanguínea viii |
| HRP20120851T1 (hr) | 2005-07-05 | 2012-11-30 | Glaxo Group Limited | Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| WO2007120767A2 (en) * | 2006-04-14 | 2007-10-25 | Amgen Inc. | Agonist erythropoietin receptor antibodies |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2785414C (en) * | 2009-12-25 | 2019-01-22 | Tomoyuki Igawa | Polypeptide modification method for purifying polypeptide multimers |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| CN104854133B (zh) | 2012-10-12 | 2018-10-30 | 新加坡科技研究局 | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 |
| WO2014177459A2 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| CN105848668A (zh) | 2013-11-04 | 2016-08-10 | 加利福尼亚大学董事会 | 治疗或预防与出血或低凝血相关联的病状的疗法 |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| JP6698102B2 (ja) | 2015-04-17 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 凝固因子と多重特異的抗体を用いた併用療法 |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| WO2016207402A1 (en) * | 2015-06-26 | 2016-12-29 | Institute For Research In Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| EP3368561B1 (en) | 2015-10-30 | 2025-09-17 | Medimmune Limited | Prevention of n-terminal truncation in igg light chains |
| WO2017110980A1 (ja) | 2015-12-25 | 2017-06-29 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| WO2017132827A1 (en) * | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| KR102625416B1 (ko) | 2016-05-16 | 2024-01-15 | 다케다 파머수티컬 컴패니 리미티드 | 항-인자 ix 파두아 항체 |
| US20190185578A1 (en) * | 2016-07-29 | 2019-06-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| PL3509637T3 (pl) | 2016-09-06 | 2025-03-10 | Chugai Seiyaku Kabushiki Kaisha | Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X |
| TN2019000164A1 (en) * | 2016-11-23 | 2020-10-05 | Bioverativ Therapeutics Inc | Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x |
| EP3577140A1 (en) | 2017-02-01 | 2019-12-11 | Novo Nordisk A/S | Procoagulant antibodies |
| WO2018145125A1 (en) | 2017-02-06 | 2018-08-09 | Applied Stemcell, Inc. | Coagulation factor viii mimetic protein and uses thereof |
| EP3615574A4 (en) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| WO2018209265A1 (en) | 2017-05-11 | 2018-11-15 | Atreca, Inc. | Anti-malarial antibodies that bind circumsporozoite protein |
| GB201709970D0 (en) * | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| PE20210005A1 (es) | 2017-09-29 | 2021-01-05 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo |
| JP7841846B2 (ja) | 2017-11-15 | 2026-04-07 | ノヴォ ノルディスク アー／エス | Ｆｘ活性化を促進する第ｘ因子結合剤 |
| US10815308B2 (en) * | 2018-12-21 | 2020-10-27 | Kymab Limited | FIXaxFX bispecific antibody with common light chain |
-
2019
- 2019-12-20 US US16/722,452 patent/US10815308B2/en active Active
- 2019-12-20 EP EP21204339.2A patent/EP4015538A1/en active Pending
- 2019-12-20 JP JP2021535950A patent/JP7530362B2/ja active Active
- 2019-12-20 US US17/311,595 patent/US20220064327A1/en not_active Abandoned
- 2019-12-20 RS RS20220069A patent/RS62848B1/sr unknown
- 2019-12-20 HU HUE19836806A patent/HUE057634T2/hu unknown
- 2019-12-20 CA CA3123177A patent/CA3123177A1/en active Pending
- 2019-12-20 DK DK19836806.0T patent/DK3723858T3/da active
- 2019-12-20 ES ES19836806T patent/ES2901683T3/es active Active
- 2019-12-20 BR BR112021012065A patent/BR112021012065A2/pt not_active Application Discontinuation
- 2019-12-20 PT PT198368060T patent/PT3723858T/pt unknown
- 2019-12-20 TW TW108146911A patent/TWI772724B/zh active
- 2019-12-20 HR HRP20220088TT patent/HRP20220088T1/hr unknown
- 2019-12-20 PL PL19836806T patent/PL3723858T3/pl unknown
- 2019-12-20 WO PCT/EP2019/086808 patent/WO2020128049A1/en not_active Ceased
- 2019-12-20 EP EP19836806.0A patent/EP3723858B1/en active Active
- 2019-12-20 SI SI201930150T patent/SI3723858T1/sl unknown
- 2019-12-20 KR KR1020217022770A patent/KR20210118085A/ko not_active Ceased
- 2019-12-20 LT LTEPPCT/EP2019/086808T patent/LT3723858T/lt unknown
- 2019-12-20 CN CN201980091786.3A patent/CN113453757B/zh active Active
-
2020
- 2020-10-06 US US17/063,905 patent/US11976135B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3123177A1 (en) | 2020-06-25 |
| TW202039584A (zh) | 2020-11-01 |
| LT3723858T (lt) | 2022-02-10 |
| US11976135B2 (en) | 2024-05-07 |
| JP2022515770A (ja) | 2022-02-22 |
| ES2901683T3 (es) | 2022-03-23 |
| US20200199250A1 (en) | 2020-06-25 |
| PT3723858T (pt) | 2022-02-02 |
| PL3723858T3 (pl) | 2022-03-07 |
| CN113453757A (zh) | 2021-09-28 |
| EP3723858A1 (en) | 2020-10-21 |
| EP4015538A1 (en) | 2022-06-22 |
| KR20210118085A (ko) | 2021-09-29 |
| US20220064327A1 (en) | 2022-03-03 |
| US20210101997A1 (en) | 2021-04-08 |
| DK3723858T3 (da) | 2022-01-24 |
| EP3723858B1 (en) | 2021-10-27 |
| US10815308B2 (en) | 2020-10-27 |
| WO2020128049A1 (en) | 2020-06-25 |
| HUE057634T2 (hu) | 2022-05-28 |
| CN113453757B (zh) | 2024-06-28 |
| HRP20220088T1 (hr) | 2022-04-15 |
| JP7530362B2 (ja) | 2024-08-07 |
| TWI772724B (zh) | 2022-08-01 |
| RS62848B1 (sr) | 2022-02-28 |
| BR112021012065A2 (pt) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3723858T (lt) | Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę | |
| IL279235A (en) | DLL3-CD3 bispecific antibodies | |
| EP3243840B8 (en) | Bispecific antibody or antibody mixture with common light chains | |
| IL279321A (en) | Anti-SIRPalpha antibody | |
| IL283812A (en) | Humanized antibody against human pd–1 | |
| ZA202004908B (en) | Bispecific antibody | |
| EP3941944A4 (en) | Claudin-6 bispecific antibodies | |
| SG11202004172UA (en) | Il2rbeta/common gamma chain antibodies | |
| GB201817172D0 (en) | Antibody | |
| CA187451S (en) | Light | |
| CA185679S (en) | Light | |
| IL253579A0 (en) | Anti-light chain substituent antibodies | |
| CA187452S (en) | Light | |
| IL289252A (en) | Ep2 antagonist | |
| IL282355A (en) | Bispecific antibodies directed to exosomes | |
| SG11202100649VA (en) | Anti-btla antibody | |
| CA187450S (en) | Light | |
| IL286757A (en) | Antibodies in specific | |
| GB201811368D0 (en) | Antibody | |
| IL286918A (en) | Bispecific antibody | |
| IL290050A (en) | Bispecific antibody | |
| SG11201802698XA (en) | Transgenic rabbit with common light chain | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| PL3763993T3 (pl) | Światło samochodowe | |
| GB201820977D0 (en) | Fixaxfx bispecific antibody with commomn light chain |